CAS: 37763-23-8; (R)-Methyl 2-Amino-2-(4-Hydroxyphenyl)Acetate

相似化合物

57591-61-4 127369-30-6 68697-60-9

上下游产品

methanol D-4-hydroxyphenylglycine Methyl 4-hydroxyphenylacetate (R)-methyl 2-amino-2-(4-hydroxyphenyl)acetateamoxicillin (6R,7S)-7-[(R)-2-Amino-2-(4-hydroxy-phenyl)-acetylamino]-3-chloro-8-oxo-1-aza-bicyclo[4.2.0]°Ct-2-ene-2-carboxylic acid (6R,7S)-7-[(R)-2-Amino-2-(4-hydroxy-phenyl)-acetylamino]-8-oxo-1-aza-bicyclo[4.2.0]°Ct-2-ene-2-carboxylic acid (4S,6R,7S)-7-[(R)-2-Amino-2-(4-hydroxy-phenyl)-acetylamino]-4-methyl-8-oxo-1-aza-bicyclo[4.2.0]°Ct-2-ene-2-carboxylic acid

4-乙酰氧基苯乙酸置于platinum(Iv) Oxide,Selenium(Iv) Oxide,氯化亚砜,二乙胺基三氟化硫,20 Wt.% Pd(Oh)2 On Activated Carbon,氢气,三氟乙酸体系中,用 二氯甲烷,水,乙酸乙酯 用作溶剂,-78.0~75.0 °C,405.33 Kpa 条件下,反应 33.25H,反应生成左旋对羟基苯甘氨酸甲酯
参考文献:通过氧化恶唑啉-恶嗪酮重排-加氢(oooh)制备α-氨基酸.范围和局限性
标题:通过氧化恶唑啉-恶嗪酮重排-加氢(oooh)制备α-氨基酸.范围和局限性
摘要:研究了氧化恶唑啉-恶嗪酮重排-氢化序列(oooh)的范围和范围,即由羧酸短而直接地不对称合成α-氨基酸.公开了迄今报道的最高的对恶嗪酮c Hydrogenn键氢化的非对映选择性(dr => 80:1),并借助从头算分子的方法使之合理化.
Doi:10.1002/asia.201100452

专利信息

专利号:US-12404534-B1
优先权日:2024-10-29
标题:Method for separating amoxicillin and phenylacetic acid from reaction solution in one-step enzymatic synthesis of amoxicillin
发明人：YANG ZHONGHUA; YIN XIAOYAN
权利人:XINGZHI COLLEGE ZHEJIANG NORMAL UNIV
摘要:A method for separating amoxicillin and phenylacetic acid from reaction solution in one-step enzymatic synthesis of amoxicillin is provided. The method employs immobilized penicillin acylase mutant to catalyze the one-step synthesis of amoxicillin from penicillin potassium, and develops a separation process for the resulting reaction mixture. The technical scheme mainly comprises: Firstly separating the immobilized penicillin acylase mutant from the reaction solution through filtration; subsequently isolating amoxicillin via crystallization; followed by separating and recovering phenylacetic acid through toluene extraction and back extraction. This separation method enables rapid and efficient isolation of amoxicillin with high production yield, achieving an average crystallization rate of 93.22%. Concurrently, it demonstrates effective separation and recovery of phenylacetic acid while allowing recyclable use of the toluene extractant.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-9101724-A1
优先权日:1989-07-27
标题 :Renal-selective prodrugs for the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as depa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitors compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-Y-glutamyl fusaric acid is preferred.

专利号:WO-9201667-A1
优先权日:1990-07-25
标题 :Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kydney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase-inhibitors, of which N-acetyl-η-glutamyl fusaric acid hydrazide [represented in formula (a)] is preferred.

专利号:US-11359224-B2
优先权日:2015-10-07
标 题 :Enzyme-immobilized porous membrane and preparation method of antibiotics using the same
发明人：PARK JI-WOONG; SHIN SUNOH
权利人:GWANGJU INST SCIENCE & TECH
摘要:The present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through dead-end filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane. n According to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by passing the solution of enzyme through the membrane. n In addition, it is possible to provide antibiotics with a high yield by preparing the antibiotics by passing the reactant solution through the enzyme-immobilized porous membrane.

专利号:CN-208485826-U
优先权日:2018-05-27
标 题:A device for coping with sudden power failure in the synthesis of L-parahydroxyphenylglycine methyl ester